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sat in the Fallot Tetralogy case increased to 96% after full occlusion. 
Conclusion: Transcatheter patch perimembranous VSD occlusion, is effective and safe. 
Lack of subaortic rim and aortic malalignment are not contrandications for the method. 
1021-158 Thrombus Formation on Atrial Septal Defect and Patent 
Foramen Ovale Closure Devices: Incidence and Clinical 
Outcome in 1,000 Consecutive Patients 
Horst Sievert. Ulrike Krumsdorf, Kathrin Horvath, Stefan Ostermayer, Kai Billinger, 
Trepels Thomas, Cardiovascular Center Bethanien, Frankfurt, Germany 
Purpose: The purpose of this study was to investigate incidence, morphology and clinl- 
cal course of thrombus formation on atrial septal defect (ASD) and patent foramen ovale 
(PFO) closure devices. 
Methods: Between August 1992 and August 2002 in lOOil consecutive patients tran- 
scatheter closure of a patent foramen ovale (n=593) or an atraf septal defect (n=407) 
was performed. Routine transoesophageal echocardiography (TEE) was performed after 
2-4 weeks and 6 months. 
Results: Thrombus formation in the left (n=ll) or the right atrium (n=6) or both (n=3) 
was found in 5/407 ASD patients (1.2%) and in 15/593 (2.5%) PFO patients. This’was 
observed after 2.4 weeks in 14. after 6 months in 3, after 1 year in 2 and after 5 years in 
1 patient. The diameter of the thrombus varied from 5 to 30 mm (12 * 7). After 4 weeks 
the TEE revealed thrombus formation in 7 % on the CardioSEAL, 6 % on the STARFlex 
and 7% on the PFO-Star occluder. in 4 % on the ASDOS occluder, in 1 % on the Helex 
occluder and in 0% on the Sideris and the Amplatzer occluder. The difference between 
the Amplatzer on one hand and the CardioSEAL, the STARFlex and the PFO-Star 
occluder on the other hand was signlflcant (p < 0.05). 
Prethrombotic disorders w:xe found in 2 PFO patients (thrombocytosis and hyperactivity 
of Factor VIII), post procedure atrial fibrillation in 4, persistent atrial septal aneurysm 
despite device implantation in 4. dewce arm fractures in 3. Significant predictors of 
thrombus were atrial fibrillation and persistent septum aneurysm. 
Three minor strokes and one TIA occurred. In 17/20 patients the thrombus resolved fol- 
lowing anticoagulatlon therapy with heparin or wariarin. In 3120 patients the thrombus 
had to be removed surgically. 
Conclusion: The incidence of thrombus formation on closure devices is low. In most of 
the patients the thrombus resolved under anticoagulation therapy without clinical conse- 
quences. 
1021-159 Favorable Right Heart Remodeling After Atrial Septal 
Defect Device Closure Even in the Over-60 Age Group 
Lorna Swan Chetan Varma, James W. Yip, Matthew Warr, Lee N. Benson, Peter 
McLaughlin, Toronto General Hospital, Toronto, ON, Canada 
Background: The degree to which the right heart remodels after atrial septal defect (ASD) 
closure is believed to be proportional to the age at the time of the procedure. It is 
unknown if there is a chronological limit to this process and whither closure over the age 
of 60 or 70 years is still associated with a beneficial effect in terms of right heart morphol- 
ogy. The aim of this study was to assess the safely and efficacy of device closure in 
those over 60 years of age. Methods: A retrospectwe study of all Amplatzer Septal 
Occluder ASD device closures from a single institution between May 1999 and August 
2002. Results: During this time period fifty subjects aged 60 years and older had ASD 
dewce closure (27% of the total cohort of 184 subjects). The mean age of this group was 
69.0 years (range 60 to 85 years). At baseline defect sizes were the same as the cohort 
under 60 years of age; as were shunt sizes (2.2:l In both groups, p=O.9). Procedural 
time, fluoroscopy time and device size used was not significantly different between the 2 
groups. Right ventricular systolic pressure (RVSP) (39.3 vs. 49.0mmHg, pcO.001) and 
right ventricular (RV) size (45.4 vs. 51.2mm, p=O.OOl), were however greater in the older 
group. Only 1 of the 4 failed deployments occurred I” the older group. Following closure 
there was a small but statistically significant decrease in RVSP and RV size (49.7vs. 
46.6mmHg, ~~0.05 and 51 .O vs. 45.6mm, p=O.O14 respectively) in the older group. The 
actual change in RVSP (10.6% vs.4.3%. p=O.72) was similar between younger and older 
groups although higher baseline values meant that the older subjects continued to have 
a higher RVSP (34.3 vs. 46.6mmHg, pcO.01) and larger RV (39.5 vs. 45.6, p<O.Ol). Con- 
clusion: Device closure of an ASD can be performed safely and simply in older subjects. 
The right heart shows signs of remodelling even in these elderly subjects. 
1021-160 Single Center Experience With Transcatheter Patent 
Foramen Ovale Closure for Paradoxical Embolism 
John F. Rhodes, Jr, Alex Abou-Chebl, Geoffrey K. Lane, Tamar J. Preminger, Cesar I. 
Mesia, Theresa Fishcher, Penelope A. Radvansky, Anthony Furlan, Larry A. Latson. The 
Cleveland Clinic Foundation, Cleveland, OH 
Background: Patients (pts) that suffer a transient ischemic attack (TIA) or a stroke in a 
pattern consistent with acute embolization are at risk for recurrent events. Closure of a 
coexistent patent foramen ovale (PFO) eliminates paradoxical embolizahon as a mecha- 
nism for recurrence. Methods: Data for all pts over a seven year period who underwent 
transcatheter (TC) PFO closure for possible embolic stroke were reviewed. Pts with neu- 
rologkxl events in the absence of a left-sided source and with a Rt. to Lt. shunt were 
identified. TC PFO closure was performed as an outpatient procedure using the standard 
CardioSEAL@ delivery technique. Follow-up evaluations were performed at 24hrs, l- 
mos, 6-mos, and yearly. Results: 142 pts met the entry criteria. Median age was 52yrs 
(range, 2k-383). Resting PFO was <3mm in all pts with a mean balloon size diameter of 
14a5mm (range: 5-22) Either a 23mm (n=41), 2Emm (n=94) or 33mm (w7) Cardlo- 
SEAL@ device were used with complete closure of the PFO in all pts. Mean fluoroscopy 
time was 14+5min. There were 2 procedure-related adverse events: l-transient brachial 
plexus palsy and l-esophageal abrasion. With a median follow-up of 28months (range 
1.3-70) there have been 9 pts reevaluated by a neurologist with a “clinical event’. Six pts 
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1021-155 Outcome of Transcatheter Closure of Muscular 
Ventricular Septal Defects Using the Amplatzer 
Ventricular Septal Defect Occluder 
Basil D. Thanopoulos, Michael L. Rigby, “Aghia Sophia” Children’s Hospital, Athens, 
Greece, Royal Brompton Hospital, London, United Kingdom 
Background: There are few reports in the literature of transcatheter closure of mUsCUlar 
ventricular septal defects (MVSDs) using the Amplatzer ventricular septal defect 
occluder (AVSDO) with encouraging initial results. In this report, we present furlher expe- 
rience and intermediate- term outcome in 28 patients with single MVSDs who underwent 
transcatheter closure with the AVSDO. Methods: Twenty-eight patients, aged 4 months 
to 16 years, with MVSDs underwent transcatheter closure using the AVSW. The device 
consists of two low profile disks made of Nitinol wire mesh with a 7 mm connecting waist. 
The prosthesis size (waist diameter) was selected to be equal to the balloon “stretched” 
diameter of the defect. A 7F to 8F sheath was used for the delivery of the AVSDO. Fluo- 
roscopy and transesophageal echocardiography were used for the guidance of the pro- 
cedure. Results: The “stretched”diameter of the defect ranged from 6 to 14 mm. 
Complete occlusion of the communication occurred in 26 I 28 patients (93% closure 
rate). One patient (an infant d-month-old) with sustained complete left bundle branch 
block after the procedure went on to developed complete heart block one year later. No 
other complications were observed during a mean follow-up of 2 years ( range, 0.25 to 4 
years). Conclusions: The AVSDO is an efficient prosthesis that can be safely used in 
the majority of patients with a single MVSDs. Further studies and long-term follow-up are 
required before this technique enters routine clinical practice. 
1021-156 Transcatheter Closure of Perimembranous Ventricular 
Septal Defects With the Amplatzer Asymmetric 
Ventricular Septal Defect Occluder: Preliminary 
Experience in Children 
Basil D. Thanocoulos, George S. Tsaousis, Evangelos Karanasios, Christodoulos 
Stefanadis, “Aghia Sophia” Children’s Hospital, Athens, Greece, lppokration University 
Hospital, Athens, Greece 
Background: The design oh previously used devices for transcatheter closure of per- 
imembranous ventricular septal defects (PMVSDs) is not ideal for this purpose and their 
use has been associated with several drawbacks. The aim of this study was to close 
PMVSDs in children using a new device the Amplatzer asymmetric ventricular septal 
defect occluder (AAVSDO). Methods: Thirteen patients, aged 1.5 to 14 years, with 
PMVSDs underwent transcatheter closure using the AAVSDO. The device consists of 
two low profile discs made of Nitinol we mesh with a 1.5 mm connecting waist. The left- 
sided disc is 5 mm towards the apex and only % mm towards the aortic valve. The right- 
sided disc is 4 mm larger than the waist. The prosthesis size (waist diameter) was cho- 
sen to be 1 2 mm larger than the PMVSD diameter. A 7F or an 8F sheath was used for 
the delivery of the AAVSDO. Fluoroscopy and transesophageal echocardiography were 
used for the gwdance of the procedure. Results: The PMVSD diameters ranged from 2 
to 8mm. The device diameters ranged from 4 to 10 mm.Overall total occlusion rate was 
92.3%. The main complication was embolization of the device in 1 / 13 patients. Tran- 
scatheter retieval was uneventful. Conclusions: The AAVSDO appears to be a promis- 
ing device for the transcatheter closure of PMVSDs in children. Further studies are 
required to document its efficacy, safety and long-term results in a larger number of 
patients 
1021-157 Transcatheter Patch Occlusion of Perimembranous 
Ventricular Septal Defects 
Eleftherios B. Sidens , Benjamin Macuil. Manolis Poursanov, Sawas Toumanides. 
Spyndon D. Moulopoulos, Athenian Institute of Pediatric Cardiology, Athens, Greece, 
Primer0 de Octubre Hospital, Mexico-City, Mexico 
Background: Transcatheter perimembranous ventricular septal defect (VSD) occlusion is 
challenging, because of the proximity of the defect to critical structures. The transcathe- 
ter patch, because of its 3-D structure has minimal rim requirements and could be ideal 
for perimembranous VSDs, includinng m&alignment ones. 
Method: Transcatheter patch occlusion was attempted in 9 perimembranous VSDs. Eight 
of the defects had significant L-R shunts (Qp:Qs larger than 2:1) and one Fallot Tetralogy 
case significant R-L shunt ( Qp:QS 0.9:l. 02 sat 72%). 
The size of the defects varied between 4-16 mm (med.8 mm) and the distance from the 
defect to the right aoriic cusp 1-5mm (med.3mm). Patient age and weight was 2-12yrs 
(med 7 yrs) and 9-20 kgs (med 15 kg) respectively. 
Results: All implantations were successful and resulted in immediate full occlusions. In 
one case, the patch moved during release and was retrieved. 
In 8 cases the supl;orting balloons were retrieved in 24(2) to 48(6) hours, resulting in full 
occlusions in 716 cases. Symptoms were improved and the 02 
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were found to have had non-focal symptoms or migraines. Two pts were considered to 
have had a TIA with the mechanism being possible cardio-embolic and I-pt had a non- 
cardio-embolic stroke due to an alternative ischemic source (ulcerated carotid plaque). 
Overall, 2/142 pts (1.4%) suffered a possible cardio-embolic neurologic event at latest 
follow-up. Conclusion: These data indicate that TC device PFO closure is safe and 
effective in preventing recurrent paradoxical embolism and should be considered an 
alternate therapy to life-long pharmacoligic therapy or surgical closure. In our patient 
population the risk of a potential recurrent neurologic event was low with no pt having a 
recurrent stroke without an alternative ischemic source. 
1021-161 Cardiopulmonary Exercise Capacity Increases in 
Patients With Atrial Septal Defect Following 
Transcatheter Closure 
Michael W. Weber, Thomas Neumann, Matthias Ftau. Christian Maikowski, Torsten Dill, 
Roland R. Brandt, Vesselin Mitrowc, Christian Hamm. Kerckhoff Heart Centre, Bad 
Nauheim, Germany 
Background: Atrlal septal defect (ASD) of the secundum is the most common congenital 
heart disease in adults. Generally closure is recommended in symptomatic patients and 
in patients with a large left to right shunt (Qp/Qs > 1.5). Only few data exists about 
improvement in exercise capacity after ASD closure. Objective of this study was to eval- 
uate exercise capacity as achieved by ergospirometly in adult patients with an ASD of 
the secundum at baseline and following transcatheter closure. 
Methods: 30 consecutive patients ( 9 male; aged 43*15 years; defect size 23 f 4,23mm; 
pulmonary-to-systemic flow ratio (QpIQs) 2.0 f 0.9; mean pulmonary ariely pressure 16 
f 4,3 mm Hg) performed exercise testing on a supine bicycle ergometer. Maximal oxy- 
gen consumption (VO, max) and oxygen consumption at the anaerobic threshold (VO, - 
AT) were assesed at baseline, 1 month and 12 month after ASD closure (Ergospirometer 
Fa. Jaeger, Germany). For ASD closure an Amplatzer - occludsr (AGA medic&, Minne- 
sota, USA) was used. 
Results: MaxImal oxygen consumption (VO, max) was reduced at baseline 14,l * 3,9 
mUminlkg with an increase after 1 month to 14,3 + 4.0 mVminlkg (n.s.) and after 12 
month to 14,9 f 4,0 mllminlkg (p < 0,05). Oxygen consumption at the anaerobic thresh- 
old (VO, - AT) was at baseline 11.1 f 2,7 mllminikg with an increase after 1 month to 
11.6 * 28 mlJmin/kg (ns.) and after 12 month to 12,6 * 3.1 mllminlkg (p < 0.01). Work 
load increased from 62 f 26 watt to 66 * 29 watt (n.s.) after 1 month and to 92 * 29 watt 
( p < 0,Ol) after 12 month. Improvement in exercise capacity (A VO, - AT) was not corre- 
lated to defect size, pulmonary-to-systemic flow ratio or mean pulmonary artery pressure 
before ASD closure. 
Conclusion: Exercise capacity of adult patients presenting with an ASD of secundum 
was reduced at baseline. Early after hanscatheter closure (1 month) there was no rele- 
vant increase in exercise capacity, but late after ASD closure (12 month) exercise capac- 
ity has increased significantly. These findings emphasize the benefit of intewentional 
ASD closure in adult patients. 
1021-162 Relief of Migraine Headaches Associated With Closure 
of Patent Foramen Ovale 
Mark Reisman, William A. Gray, John V. Olsen, Swedish Cardiovascular Research, 
Seattle, WA 
Background: Previous reports have documented that the incidence of PFO in the 
migraine patient population is at least twice that of the general population. However few 
reports demonstrate the potential impact of PFO closure on the relief of migraine head- 
aches. Recently introduced percutaneous closure devices for treating patent foramen 
wale (PFO) provide a low-risk and effective alternative to surgical closure or chronic 
warfarin therapy in patients with paradoxic emboli and stroke. 
Methods: Between 4101 and 7102 69 PFOs were closed usma the NMT Cardweal 
device for patients with a history of prior TIA or stroke. All patients had positive transcra- 
nial Doooler (TCDl and oositive contrast transthoracic echo 1cTTE) or transesoohaaeal 
(cTEE) studies. Tisting ‘for PFO closure was obtained at 1, ‘3, anb 6 months dy c?CD 
and cTTE or until complete closure was identified. Once closure was documented, all 
patients completed a questionnaire to identify the presence, frequency and type of 
migraine headache (MH) episodes occurring pre- and post-procedure. MH, and associ- 
ated aura were defined according to the criteria of the International Headache Society. 
Patients were not informed that PFO closure might have any impact on MH prior to pro- 
cedure. 
Results: Among our total of 69 PFO closures during this interval, 16 (26 %) patients had 
MH and 14/16 had aura. The average age of MH patients was 44 years and 55% were 
female. Percutaneous closure was successful in 16 patients and 2 patients were closed 
surgically. Follow-up studies showed complete PFO closure in all patients. 1 patient was 
lost to follow-up. Of the patients with successful closure 7 (36%) had complete relief of 
MH and 6 (44%) had partial relief. There was a cumulative reduction in frequency of MH 
from 3.06 episodeslptlmonth to .05 episodeslptlmonth. 
Conclusion: This observational study demonstrated that PFO closure can reduce, and 
frequently eliminate, migraine episodes and suggests that in some patients with MH, 
PFOs may have a role in the genesis of headache. The RELIEF registry will study this 
population further. 
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1046-l 55 Influence of Pacemaker Lead Localization on 
Reintervention Rate in Children 
Rainer Schrepf, Manfred Vogt, Viola Helming, Christoph Kolb, John Hess, Medical Clinic 
of the University of Munich lnnenstadt, Munich, Germany, German Heart Center 
Munich, Munich, Germany 
Pm-studies in our institution m 1996 showed an increased (e-intervention rate, a reduced 
pacemaker longevity respectively in epicardial lead positioning (4.1~2.6~. median 3.7~) 
when compared to the transvenous approach (6.4*1.6y, mizdian 6.5~) (p-zO.009) in chil- 
dren. This is mainly due to an increase I” pacing and sensing thresholds. The propoltion 
between epicardial and endocardial leads was 3:i (45 vs.15 patients). We therefore 
changed our standard approach to transvenous Implantation where applicable in 1997. 
We included all 51 consecutive children that were implanted between 1.1.1997 and 
31.12.2001 in our institution into our follow-up study. 25 patients obtained transvenous 
lead implantation, 26 had to be provided with epicardial leads due to the underlying heart 
disease and performed cardiac surgery or limitations in age, weight or size of the chil- 
dren. 29 were male (57%), 22 were female (43%). Mean age at implantation was 
6.7*7.2y, median 7.9y (p < 0.05 compared to the previous period), size and weight did 
not differ significantly The smallest child to obtain an epwardial pacing system had two 
days, minimum weight was 2.6kg compared to 10 months and 7.6kg in the sndocardial 
group. Comparing the patient population before and after 1997 the number of dual cham- 
ber pacemakers increased from n=4 (7%) (until 1996) to n=30 (59%) (from 1997) signifi- 
cantly (p < 0.001). The use of atrial leads increased from 6 to 31 whereas the percentage 
of endocardial applications remained stable without signifwmt difference. The percent- 
age of endocardial ventricular leads increased significantly (p = 0.006) from 23 (n=l3) to 
46 (n=24). 
9 of the 26 patients with epicardial leads had a m-intervention compared to 6 of the 25 
children with a transvenous system (p = II.?..). The mean time to re-intervention did not 
differ significantly in both groups (epi: l.O+l.ly vs. endo: 0.3+0.3y). 
Conclusion: The usage of transvenous endocardial leads and dual chamber systems in 
children is safe and well tolerated without increase in complication rate. Cut of in age and 
weight for the extensive application of transvenous leads in our patient population was 
roughly one year and 10 kg. 
1046-156 Magnetic Resonance Imaging and the Diagnosis of 
Right Ventricular Dysplasia in Children: An Institutional 
Experience 
Mark A. Foael, Paul M. Weinberg, Larry Rhodes, Children’s Hospital of Philadelphia, 
Philadelphia, PA, University of Pennsylvania School of Medicine, Philadelphia, PA 
Background: Magnetic resonance imaging (MRI) has been helpful in adults to diagnose 
of right ventricular (RV) dysplasia. Short of direct observation, no gold standard exists. 
Diagnostic criteria by MRI includes right atrial and ventrwlar dilation, regional RV wall 
motion abnormalities, RV outflow tract ectasia and RV myocardial fatty infiltration. Meth- 
ods: To determine whether these diagnostic criteria are useful in children referred for 
cardiac MRI. the images and records of 44 patients over an 7 year period from our insti- 
tution were reviewed. Referral diagnoses included a history of ventricular tachycardia. 
palpitations, syncope, near sudden death or a family history of RV dysplasia. 4 families 
were studied with parents who had RV dysplasia diagnosed by surgery, explanted heart, 
or MRI. MRI imaging included Tl images with and without fat saturation, tine MRI. l- 
dimensional myocardial stripes of the RV, and phase encoded velocity mapping. 
Results: None of the 44 patients met more than 2 of the criteria and only 2 patients met 
one or 2 criteria. For questionable regional wall motion abnormalities, l-dimensional 
myocardial tagging was able to identify normal myocardial shortening. Conclusions: 
Cardiac MRI on children with a h&tory suspicious of RV dysplasia is a low yield test. This 
may be due to evolving nature of the disease which does not manifest itself from a mor- 
phologic or ventricular function standpoint until later on in development. Follow-up stud- 
ies as the patients age may be advantageous. 
